Site Specific Knock-In Genome Editing in Human HSCs Using Baboon Envelope gp Pseudotypedviral Derived “Nanoblades” Loaded with Cas9/sgRNA Combined with Donor Encoding AAV-6

• Autores: Gutierrez, Alejandra; Abrey Recalde, Maria Jimena; Mangeot, Philippe E.; Costa, Caroline; Bernandin, Ornellie; Fusil, Floriane; Froment, Gisèle; Martin, Francisco; Bellabdelah, Karim; Ricci, Emiliano P.; Ayuso, Eduard; Cosset, François loic; Verhoeyen, Els
• Año de publicación: 2019
• Idioma: inglés
• Tipo de recurso: documento de conferencia
• Materia: NANOBLADES; GENE EDITING; CRISPR
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

Programmable nucleases have enabled rapid and accessible genome engineering in eukaryotic cells and living organisms. Here, we have designed ?Nanoblades?, a new technology that will deliver a genomic cleaving agent into cells. These are genetically modified Murine Leukemia Virus (MLV) or HIV derived virus like particle (VLP), in which the viral structural protein Gag has been fused to the Cas9. These VLPs are thus loaded with Cas9 protein together with the guide RNAs. Thus, nanoblades are devoid of any viral-derived genetic material. Highly efficient gene editing was obtained in cell lines, IPS cells and primary mouse and human cells (Mangeot et al. Nature Communication, 2019). However, their delivery into target cells can be technically challenging when working with primary immune cells. Now we showed that nanoblades were remarkably efficient for entry into human T, B and hematopoietic stem cells thanks to their surface co-pseudotyping with baboon retroviral and VSVG envelope glycoproteins. We were able to induce efficient, transient and very rapidlygenome-editing in human induced pluripotent stem cells reaching up to 70% in the empty spiracles homeobox 1 (EMX1) and muscular dystrophy (MD) gene locus. A brief nanoblade incubation of primary human T and B cells resulted in 40% and 20% editing of the Wiskott-Aldrich syndrome (WAS) gene locus, while hematopoietic stem cells treated for 18 h with nanoblades allowed 30-40% gene editing in the WAS gene locus and up to 80% for the Myd88 genomic target. Moreover, for the HIV- and MLV-derived nanoblades no cell toxicity and low to undetectable off-target effects were demonstrated.Finally, we also treated hHSCs with nanoblades in combination with an AAV-6 donor encoding vector resulting in over 20% of stable expression cassette knock-in into the WAS gene locus. Currently, we are evaluating these gene modified HSCs for their long-term reconstitution of NOD/SCIDgC-/- mice.Summarizing, this new technology is simple to implement in any laboratory, shows high flexibility for different targets including primary immune cells of murine and human origin, is relatively inexpensive and therefore have important prospects for basic and clinical translation in the area of gene therapy.
Fil: Gutierrez, Alejandra. Inserm; Francia
Fil: Abrey Recalde, Maria Jimena. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina. Inserm; Francia
Fil: Mangeot, Philippe E.. Inserm; Francia
Fil: Costa, Caroline. Inserm; Francia
Fil: Bernandin, Ornellie. Inserm; Francia
Fil: Fusil, Floriane. Inserm; Francia
Fil: Froment, Gisèle. Inserm; Francia
Fil: Martin, Francisco. Inserm; Francia
Fil: Bellabdelah, Karim. Universidad de Granada; España
Fil: Ricci, Emiliano P.. Inserm; Francia
Fil: Ayuso, Eduard. Universite de Nantes; Francia
Fil: Cosset, François loic. Inserm; Francia
Fil: Verhoeyen, Els. Inserm; Francia
American Society of Cell and Gene Therapy 22nd Annual Metting
Washington
Estados Unidos
American Society of Cell and Gene Therapy